Table 3.

Results from the Univariate Analysis of Factors Associated with Overall Survival and Relapse-Free Survival after Unrelated Donor HSCT

	Survival			RFS
	RH	95% CI	P-value	RH	95% CI	P-Value
LCC*	1.04	0.54-2.03	.90	0.91	0.46-1.81	.78
ALC*	0.35	0.15-0.85	.02	0.30	0.12-0.72	.007
ANC*	1.20	0.59-2.44	.61	1.23	0.71-2.14	.46
HB*	0.83	0.68-1.01	.06	0.84	0.70-1.02	.08
Platelet*	0.93	0.88-0.99	.022	0.95	0.90-0.99	.04
Patient age*	1.13	0.92-1.37	.24	1.10	0.91-1.33	.34
Donor age*	0.91	0.59-1.40	.66	0.92	0.61-1.38	.68
NC dose*	1.06	0.82-1.37	.66	1.02	0.79-1.32	.87
CD34 dose*	1.04	0.99-1.08	.07	1.04	1.00-1.09	<.05
Low risk versus high risk	1.42	0.76-2.66	.28	1.30	0.71-2.38	.40
Acute leukemia versus all others	1.60	0.84-3.06	.15	1.43	0.78-2.63	.25
TBI versus Busulfan	0.88	0.47-1.64	.68	0.86	0.47-01.58	.63
aGVHD 0-1 versus aGVHD II-IV	3.90	2.04-7.44	.00004	3.35	1.83-6.16	.0001
FD to MR versus all other combinations	1.35	0.56-3.26	.50	1.19	0.50-2.81	.70
PBSC versus BM	1.39	0.73-2.66	.32	1.22	0.67-2.24	.53
cGVHD yes/no	1.05	0.50-2.21	.89	0.90	0.44-1.87	.78
G-CSF yes/no	1.95	0.93-4.12	.08	2.05	1.01-4.16	<.05

LCC indicates day 30 leukocyte cell count; ALC, day 30 absolute lymphocyte count; ANC, day 30 absolute neutrophil count; HB, day 30 hemoglobin level; platelets, day 30 platelet count; NC dose, nucleated cell dose in graft (× 10⁸/kg), CD34, CD34⁺ cell dose in graft (× 10⁶/kg); low risk, CR1/CP1; high risk; >CR1/CP1; TBI, total body irradiation; aGVHD, acute graft-versus-host disease; FD to MR; female donor to male recipient; BM, bone marrow; PBSC, peripheral blood stem cells; cGVHD; chronic graft-versus-host disease; RFS, relapse-free survival; CI, confidence interval; G-CSF, granulocyte-colony stimulating factor; RH, relative hazard.

^*Analyzed as continuous variable.